GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
X

Xenetic Biosciences XBIO · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.80

-3.88%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Xenetic Biosciences

From its filings with the US Securities and Exchange Commission

SEC filings

Xenetic Biosciences is based in Framingham, Massachusetts and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker XBIO. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $3.0m and a net loss of $2.7m. At that date it held total assets of $8.4m and shareholders' equity of $7.4m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
7 Nov 2016
Employees
2
Head office
945 CONCORD ST., FRAMINGHAM, MA, 01701
Incorporated in
NV
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. James ParslowInterim Chief Executive Officer, Chief Financial Officer, Corporate Secretary$481,168
  • Dr. Dmitry GenkinDirector$49,980
  • Mr. Moshe MizrahyDirector$12,329
  • Dr. Grigory BorisenkoIndependent Director$51,721
  • Mr. Firdaus DastoorIndependent Director$51,721
  • Dr. Roger KornbergIndependent Director$51,721
  • Dr. Alexey VinogradovIndependent Director$51,721
  • Ms. Jenene ThomasInvestor Relations, since 2021

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company has a focused approach on cell-based therapeutics targeting B-cell receptors for B-cell lymphoma treatment.
  • The company has a personalized CAR T platform technology called XCART for targeting tumor neoantigens.
  • PolyXen drug delivery platform is leveraged through partnerships with biotechnology and pharmaceutical companies.

Weaknesses

  • The company employs only 2 full-time employees, indicating limited operational capacity.
  • The source description mentions 4 employees, conflicting with the provided employee count of 2.
  • The company's focus on a niche therapeutic area may limit market reach.

Opportunities

  • Advancing XCART technology could lead to new treatment options for B-cell lymphomas.
  • Partnerships using PolyXen platform may expand the company's market presence.
  • Growing interest in personalized medicine could increase demand for the company's therapies.

Threats

  • The company's small size and limited employee count may hinder research and development efforts.
  • Conflicting employee count information may indicate internal management issues.
  • Competition in the biotechnology sector could impact the company's market position.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.